Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Soumitro Pal, Ph.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Overview
Major Research Interest:

(a) Roles of different chemokines and chemokine receptors in the progression of human cancers. Recent reports suggest that different chemokines and their receptors play critical role(s) in tumor progression and tumor metastasis. We plan to study the role(s) of oncogenes and some kinases in modulating the expression of different chemokines/chemokine receptors in human breast cancer and renal cancer. Our studies are focused on the signal transduction pathways that are involved in the development and progression of tumor. We have shown that the oncogenic ras pathway can modulate the expression of the splice variants of the chemokine receptor CXCR3, and may play a critical role in the development and rapid progression of cancer (Datta & Pal et al, Cancer Research, 2006).

(b) Mechanism(s) for the development of post-transplantation cancer, and primarily renal and skin cancer. We plan to study the role of different immunosuppressive drugs in modulating the expression of angiogenic cytokines (like vascular endothelial growth factor) and chemokines post-transplantation. We have recently shown that the calcineurin inhibitors (used in transplant patients) can promote rapid progression of human renal cancer through the overexpression of the angiogenic cytokine VEGF (Basu & Pal et al, Cancer Research, 2008; Basu & Pal et al, J Biological Chemistry, 2010). We have also demonstrated that the calcineurin inhibitors can activate the ras oncogenic pathway(s) in human renal cancer cells (Datta & Pal et al, Cancer Research, 2009).

(c) Role of the cytoprotective enzyme heme oxygenase-1 (HO-1) in regulating the expression of different genes for the effective repair mechanism(s) of human renal tubular epithelial cells in response to various shock and injury. We have demonstrated that during renal injury, HO-1 may play a critical role in the repair mechanism(s) by regulating several genes, including angiogenic factors (Laxmanan & Pal et al, J Am Soc of Nephrology, 2005; Datta & Pal et al, Am Journal of Physiology, 2007).

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R03CA215926 (PAL, SOUMITRO) Jun 5, 2018 - Jun 30, 2020
    NIH/NCI
    CXCR3-B-mediated novel growth-inhibitory signals in breast cancer cells
    Role: Principal Investigator
  2. R01CA222355 (PAL, SOUMITRO) Jun 1, 2018 - May 31, 2023
    NIH/NCI
    Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer
    Role: Principal Investigator
  3. R01CA193675 (PAL, SOUMITRO) Jan 1, 2016 - Dec 31, 2020
    NIH/NCI
    Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer
    Role: Principal Investigator
  4. R21CA191735 (PAL, SOUMITRO) Jul 15, 2015 - Jun 30, 2017
    NIH/NCI
    Novel Role of Honokiol in Preventing Cancer during Immune Suppression
    Role: Principal Investigator
  5. R21CA172946 (PAL, SOUMITRO) Sep 1, 2013 - Aug 31, 2015
    NIH/NCI
    Novel Therapeutic Targets For Calcineurin Inhibitor-Induced And mTOR-Mediated Can
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Balan M, Pal S. Correction: A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem. 2020 Jul 24; 295(30):10509. PMID: 32709763.
    Citations:    
  2. Sabarwal A, Chakraborty S, Mahanta S, Banerjee S, Balan M, Pal S. A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape. Cancers (Basel). 2020 Jul 03; 12(7). PMID: 32635337.
    Citations:    
  3. Chakraborty S, Balan M, Flynn E, Zurakowski D, Choueiri TK, Pal S. Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. Oncogenesis. 2019 Jan 15; 8(2):7. PMID: 30647407.
    Citations:    
  4. Balan M, Chakraborty S, Pal S. Signaling Molecules in Posttransplantation Cancer. Clin Lab Med. 2019 03; 39(1):171-183. PMID: 30709505.
    Citations:    Fields:    
  5. Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S. Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 2017 Nov 28; 8(61):103428-103436. PMID: 29262573.
    Citations:    Fields:    
  6. Balan M, Chakraborty S, Flynn E, Zurakowski D, Pal S. Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth. Sci Rep. 2017 07 19; 7(1):5900. PMID: 28724911.
    Citations: 1     Fields:    
  7. Loretelli C, Moore RF, Ben Nasr M, Dellepiane S, Balan M, Mounayar M, Usuelli V, El Essawy B, D'Addio F, Stemmer-Rachamimov AO, Zuccotti GV, Pal S, Fiorina P, Abdi R. Immunoevasion rather than intrinsic oncogenicity may confer MSCs from non-obese diabetic mice the ability to generate neural tumors. Acta Diabetol. 2017 Jul; 54(7):707-712. PMID: 28224274.
    Citations:    Fields:    
  8. Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015 Mar 27; 290(13):8110-20. PMID: 25645920.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  9. Medvetz D, Sun Y, Li C, Khabibullin D, Balan M, Parkhitko A, Priolo C, Asara JM, Pal S, Yu J, Henske EP. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting. Mol Cancer Res. 2015 Jan; 13(1):50-62. PMID: 25185584.
    Citations: 6     Fields:    Translation:HumansCells
  10. Balan M, Pal S. A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem. 2014 Feb 07; 289(6):3126-37. PMID: 24366869.
    Citations: 11     Fields:    Translation:HumansCells
  11. Banerjee P, Basu A, Arbiser JL, Pal S. The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Lett. 2013 Sep 28; 338(2):292-9. PMID: 23752066.
    Citations: 7     Fields:    Translation:HumansCells
  12. Banerjee P, Basu A, Wegiel B, Otterbein LE, Mizumura K, Gasser M, Waaga-Gasser AM, Choi AM, Pal S. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J Biol Chem. 2012 Sep 14; 287(38):32113-23. PMID: 22843690.
    Citations: 23     Fields:    Translation:HumansCells
  13. Basu A, Banerjee P, Pal S. Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression. Cell Cycle. 2012 Feb 15; 11(4):633-4. PMID: 22293493.
    Citations: 1     Fields:    Translation:Humans
  14. Basu A, Liu T, Banerjee P, Flynn E, Zurakowski D, Datta D, Viklicky O, Gasser M, Waaga-Gasser AM, Yang J, Pal S. Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. Cancer Lett. 2012 Aug 28; 321(2):179-86. PMID: 22343319.
    Citations: 2     Fields:    Translation:AnimalsCells
  15. Bruneau S, Datta D, Flaxenburg JA, Pal S, Briscoe DM. TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor. Biochem Biophys Res Commun. 2012 Mar 02; 419(1):66-71. PMID: 22326918.
    Citations: 6     Fields:    Translation:HumansCells
  16. Basu A, Banerjee P, Contreras AG, Flynn E, Pal S. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One. 2011; 6(8):e23919. PMID: 21886838.
    Citations: 8     Fields:    Translation:HumansCells
  17. Banerjee P, Basu A, Datta D, Gasser M, Waaga-Gasser AM, Pal S. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J Biol Chem. 2011 Sep 23; 286(38):33580-90. PMID: 21808062.
    Citations: 20     Fields:    Translation:HumansCells
  18. Datta D, Banerjee P, Gasser M, Waaga-Gasser AM, Pal S. CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem. 2010 Nov 19; 285(47):36842-8. PMID: 20855888.
    Citations: 21     Fields:    Translation:HumansCells
  19. Basu A, Datta D, Zurakowski D, Pal S. Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem. 2010 Aug 13; 285(33):25196-202. PMID: 20554520.
    Citations: 15     Fields:    Translation:HumansCells
  20. Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K, Pal S, Briscoe DM. Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol. 2010 Jan 15; 184(2):545-9. PMID: 20008289.
    Citations: 23     Fields:    Translation:HumansCells
  21. Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, Pal S. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res. 2009 Dec 01; 69(23):8902-9. PMID: 19903851.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  22. Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, Briscoe DM. mTOR-understanding the clinical effects. Transplant Proc. 2008 Dec; 40(10 Suppl):S9-S12. PMID: 19100913.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  23. Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, Briscoe DM. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol. 2008 Dec 01; 181(11):8088-95. PMID: 19018001.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  24. Datta D, Contreras AG, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol. 2008 Dec; 19(12):2437-46. PMID: 18832436.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  25. Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 2008 Jul 15; 68(14):5689-98. PMID: 18632621.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  26. Briscoe DM, Pal S. Assessing the vascular effects of early erythropoietin use in pediatric renal transplant recipients. Nat Clin Pract Nephrol. 2008 Mar; 4(3):136-7. PMID: 18091722.
    Citations: 1     Fields:    Translation:Humans
  27. Datta D, Dormond O, Basu A, Briscoe DM, Pal S. Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2007 Oct; 293(4):F1222-30. PMID: 17652371.
    Citations: 6     Fields:    Translation:HumansCells
  28. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 2006 Oct 01; 66(19):9509-18. PMID: 17018607.
    Citations: 52     Fields:    Translation:HumansCells
  29. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol. 2006 Mar 01; 176(5):3098-107. PMID: 16493069.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  30. Laxmanan S, Datta D, Geehan C, Briscoe DM, Pal S. CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol. 2005 Sep; 16(9):2714-23. PMID: 16033859.
    Citations: 11     Fields:    Translation:HumansCells
  31. Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol. 2004 Jun 15; 172(12):7503-9. PMID: 15187129.
    Citations: 14     Fields:    Translation:HumansCells
  32. Lapchak PH, Melter M, Pal S, Flaxenburg JA, Geehan C, Frank MH, Mukhopadhyay D, Briscoe DM. CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island. Am J Physiol Renal Physiol. 2004 Sep; 287(3):F512-20. PMID: 15140761.
    Citations: 6     Fields:    Translation:HumansCells
  33. Neid M, Datta K, Stephan S, Khanna I, Pal S, Shaw L, White M, Mukhopadhyay D. Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J Biol Chem. 2004 Feb 06; 279(6):3941-8. PMID: 14604996.
    Citations: 14     Fields:    Translation:HumansCells
  34. Basu A, Basu I, Chakraborty A, Pal S, Chattopadhyay U. Detection and purification of a novel 72 kDa glycoprotein male breast tumor associated antigen. Int J Cancer. 2003 Jun 20; 105(3):377-83. PMID: 12704672.
    Citations:    Fields:    Translation:Humans
  35. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 2001 Sep 15; 61(18):6952-7. PMID: 11559575.
    Citations: 57     Fields:    Translation:HumansCells
  36. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med. 2001 May; 7(5):569-74. PMID: 11329058.
    Citations: 77     Fields:    Translation:HumansAnimalsCells
  37. Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, Mukhopadhyay D, Briscoe DM. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000 Dec 01; 96(12):3801-8. PMID: 11090063.
    Citations: 41     Fields:    Translation:HumansAnimalsCells
  38. Pal S, Datta K, Khosravi-Far R, Mukhopadhyay D. Role of protein kinase Czeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J Biol Chem. 2001 Jan 26; 276(4):2395-403. PMID: 11060301.
    Citations: 16     Fields:    Translation:Cells
  39. Pal S, Iruela-Arispe ML, Harvey VS, Zeng H, Nagy JA, Dvorak HF, Mukhopadhyay D. Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Microvasc Res. 2000 Sep; 60(2):112-20. PMID: 10964585.
    Citations: 6     Fields:    Translation:Animals
  40. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem. 2000 Jul 07; 275(27):20700-6. PMID: 10748176.
    Citations: 18     Fields:    Translation:HumansCells
  41. Pal S, Claffey KP, Cohen HT, Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem. 1998 Oct 09; 273(41):26277-80. PMID: 9756852.
    Citations: 25     Fields:    Translation:HumansCells
  42. Ghosh S, Pal S, Das S, Dasgupta SK, Majumdar S. Lipoarabinomannan induced cytotoxic effects in human mononuclear cells. FEMS Immunol Med Microbiol. 1998 Jul; 21(3):181-8. PMID: 9718207.
    Citations: 4     Fields:    Translation:HumansCells
  43. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem. 1997 Oct 31; 272(44):27509-12. PMID: 9346879.
    Citations: 25     Fields:    Translation:HumansCells
  44. Pal S, Sanyal U, Chattopadhyay U. Purification and characterization of a new 85-kDa glycoprotein antigen from human breast tumor. Int J Cancer. 1995 Mar 16; 60(6):759-65. PMID: 7896441.
    Citations: 2     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Pal's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (254)
Explore
_
Co-Authors (25)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.